• Exchanges

Daré Bioscience & Orbis Biosciences to Collaborate on Injectables


Daré Bioscience and Orbis Biosciences have agreed to collaborate on development of two etonogestrel-based injectable contraceptives. The products under development will target 6- and 12-month durations of efficacy, improved side effect profiles compared to current injectables, and a more predictable return to fertility.  Currently marketed injectables provide three months of contraceptive protection. The collaboration will leverage pre-clinical studies completed on this concept under the FHI 360-led Contraceptive Technology Innovation Initiative, supported by the Bill & Melinda Gates Foundation.

0 views

Get in touch with us

  • Twitter
linkedin social bar.png

Powered by